Ratings by Raymond James (Martin Auster)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/3/2026 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/26/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/19/2026 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Strong Buy (N/A) |
8.16 (7.99) |
-2.08% | Details | |
| 2/12/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | Evommune Inc | EVMN | New Coverage | Strong Buy (N/A) |
16.08 (26.50) |
64.8% | Details | |
| 12/19/2025 | Septerna Inc | SEPN | New Coverage | Strong Buy (N/A) |
27.54 (28.78) |
4.5% | Details | |
| 12/12/2025 | Phathom Pharmaceuticals | PHAT | New Coverage | Strong Buy (N/A) |
14.55 (10.67) |
-26.67% | Details | |
| 12/8/2025 | Disc Medicine | IRON | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/13/2025 | Maze Therapeutics | MAZE | New Coverage | Outperform (N/A) |
32.56 (44.83) |
37.68% | Details | |
| 10/31/2025 | Disc Medicine | IRON | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/30/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/17/2025 | Ascendis Pharma | ASND | New Coverage | Strong Buy (N/A) |
207.12 (240.65) |
16.19% | Details | |
| 8/7/2025 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/6/2025 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/1/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2025 | Alnylam Pharmaceuticals | ALNY | New Coverage | Outperform (N/A) |
324.79 (320.66) |
-1.27% | Details | |
| 7/30/2025 | Cytokinetics | CYTK | Downgrade | Market Perform (Outperform) |
36.63 (60.41) |
64.92% | Details | |
| 7/30/2025 | Edgewise Therapeutics | EWTX | New Coverage | Strong Buy (N/A) |
14.26 (27.82) |
95.09% | Details | |
| 7/30/2025 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
46.23 (65.36) |
41.38% | Details | |
| 7/29/2025 | Scholar Rock | SRRK | New Coverage | Strong Buy (N/A) |
37.09 (45.29) |
22.11% | Details |
